These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 35466945)

  • 1. Huntington's Disease Regulatory Science Consortium: Accelerating Medical Product Development.
    Turner EC; Gantman EC; Sampaio C; Sivakumaran S
    J Huntingtons Dis; 2022; 11(2):97-104. PubMed ID: 35466945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Emerging Landscape of Small-Molecule Therapeutics for the Treatment of Huntington's Disease.
    Ahamad S; Bhat SA
    J Med Chem; 2022 Dec; 65(24):15993-16032. PubMed ID: 36490325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Volumetric MRI-Based Biomarkers in Huntington's Disease: An Evidentiary Review.
    Kinnunen KM; Schwarz AJ; Turner EC; Pustina D; Gantman EC; Gordon MF; Joules R; Mullin AP; Scahill RI; Georgiou-Karistianis N;
    Front Neurol; 2021; 12():712555. PubMed ID: 34621236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recommendations to Optimize the Use of Volumetric MRI in Huntington's Disease Clinical Trials.
    Kinnunen KM; Mullin AP; Pustina D; Turner EC; Burton J; Gordon MF; Scahill RI; Gantman EC; Noble S; Romero K; Georgiou-Karistianis N; Schwarz AJ
    Front Neurol; 2021; 12():712565. PubMed ID: 34744964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downregulation of glial genes involved in synaptic function mitigates Huntington's disease pathogenesis.
    Onur TS; Laitman A; Zhao H; Keyho R; Kim H; Wang J; Mair M; Wang H; Li L; Perez A; de Haro M; Wan YW; Allen G; Lu B; Al-Ramahi I; Liu Z; Botas J
    Elife; 2021 Apr; 10():. PubMed ID: 33871358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Xyloketal-derived small molecules show protective effect by decreasing mutant Huntingtin protein aggregates in Caenorhabditis elegans model of Huntington's disease.
    Zeng Y; Guo W; Xu G; Wang Q; Feng L; Long S; Liang F; Huang Y; Lu X; Li S; Zhou J; Burgunder JM; Pang J; Pei Z
    Drug Des Devel Ther; 2016; 10():1443-51. PubMed ID: 27110099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Foundation-directed therapeutic development in Huntington's disease.
    Dominguez C; Munoz-Sanjuan I
    J Med Chem; 2014 Jul; 57(13):5479-88. PubMed ID: 24432836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Translating cell therapies for neurodegenerative diseases: Huntington's disease as a model disorder.
    Rosser AE; Busse ME; Gray WP; Badin RA; Perrier AL; Wheelock V; Cozzi E; Martin UP; Salado-Manzano C; Mills LJ; Drew C; Goldman SA; Canals JM; Thompson LM
    Brain; 2022 Jun; 145(5):1584-1597. PubMed ID: 35262656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Features of Huntington's Disease.
    Ghosh R; Tabrizi SJ
    Adv Exp Med Biol; 2018; 1049():1-28. PubMed ID: 29427096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic targeting of Huntington's disease: Molecular and clinical approaches.
    Kumar D; Hasan GM; Islam A; Hassan MI
    Biochem Biophys Res Commun; 2023 May; 655():18-24. PubMed ID: 36913762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survey of the Huntington's Disease Patient and Caregiver Community Reveals Most Impactful Symptoms and Treatment Needs.
    Simpson JA; Lovecky D; Kogan J; Vetter LA; Yohrling GJ
    J Huntingtons Dis; 2016 Dec; 5(4):395-403. PubMed ID: 27983566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Azadiradione Restores Protein Quality Control and Ameliorates the Disease Pathogenesis in a Mouse Model of Huntington's Disease.
    Singh BK; Vatsa N; Nelson VK; Kumar V; Kumar SS; Mandal SC; Pal M; Jana NR
    Mol Neurobiol; 2018 Aug; 55(8):6337-6346. PubMed ID: 29294248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lowering Mutant Huntingtin Levels and Toxicity: Autophagy-Endolysosome Pathways in Huntington's Disease.
    Valionyte E; Yang Y; Roberts SL; Kelly J; Lu B; Luo S
    J Mol Biol; 2020 Apr; 432(8):2673-2691. PubMed ID: 31786267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Huntington's Disease: New Frontiers in Therapeutics.
    Pan L; Feigin A
    Curr Neurol Neurosci Rep; 2021 Feb; 21(3):10. PubMed ID: 33586075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic Update on Huntington's Disease: Symptomatic Treatments and Emerging Disease-Modifying Therapies.
    Dash D; Mestre TA
    Neurotherapeutics; 2020 Oct; 17(4):1645-1659. PubMed ID: 32705582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transgenic animal models for study of the pathogenesis of Huntington's disease and therapy.
    Chang R; Liu X; Li S; Li XJ
    Drug Des Devel Ther; 2015; 9():2179-88. PubMed ID: 25931812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of mutant and total huntingtin expression in Huntington's disease murine models.
    Fodale V; Pintauro R; Daldin M; Altobelli R; Spiezia MC; Bisbocci M; Macdonald D; Bresciani A
    Sci Rep; 2020 Dec; 10(1):22137. PubMed ID: 33335120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Translating Antisense Technology into a Treatment for Huntington's Disease.
    Lane RM; Smith A; Baumann T; Gleichmann M; Norris D; Bennett CF; Kordasiewicz H
    Methods Mol Biol; 2018; 1780():497-523. PubMed ID: 29856033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroprotective possibilities for Huntington's disease.
    Emerich DF
    Expert Opin Biol Ther; 2001 May; 1(3):467-79. PubMed ID: 11727519
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.